Voxilaprevir

DRUG4 trials

Sponsors

Gilead Sciences, M.D. Anderson Cancer Center

Conditions

HCV InfectionHepatitis C Virus InfectionLiver Cancer

Phase 1

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

CompletedNCT02185794

Gilead SciencesHepatitis C Virus Infection

Start: 2014-06-13End: 2015-09-28Updated: 2020-09-17

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

CompletedNCT02397707

Gilead SciencesHCV Infection

Start: 2015-03-24End: 2016-03-04Updated: 2020-04-09

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

CompletedNCT02402452

Gilead SciencesHCV Infection

Start: 2015-05-05End: 2015-09-28Updated: 2020-03-20

Phase 4

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

TerminatedNCT05717400

M.D. Anderson Cancer CenterLiver Cancer

Start: 2023-03-17End: 2024-08-29Updated: 2024-12-31

Related Papers

Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor

Antiviral Therapy2017-05-0127 citations